Meiragtx Holdings plc cash flow statement
In fiscal 2025, Meiragtx Holdings plc's operations generated −$46.4m of cash; it spent $3.8m on capital projects, leaving free cash flow of −$50.2m.
Cash flow statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 20 | −64 | −11 | −73 | −105 | −104 | −46 | 14 |
| Depreciation and amortisation | 2 | 4 | 8 | 9 | 14 | 13 | 13 | 12 |
| Stock-based pay | 16 | 18 | 21 | 29 | 28 | 25 | 22 | 19 |
| Capital spending | 9 | 21 | 46 | 45 | 20 | 5 | 4 | 3 |
| Free cash flow | 11 | −85 | −57 | −118 | −126 | −109 | −50 | 10 |
| Free cash flow after stock pay | −5 | −103 | −78 | −147 | −153 | −135 | −72 | −9 |
| Shares issued | 155 | 87 | — | 25 | 92 | 59 | 15 | 133 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −25 | −23 | −37 | −44 | −12 | 47 | 18 | −39 |
| Depreciation and amortisation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Stock-based pay | 6 | 6 | 5 | 6 | 6 | 6 | 4 | 4 |
| Capital spending | 1 | 1 | 2 | 1 | 1 | 0 | 2 | 0 |
| Free cash flow | −26 | −24 | −39 | −45 | −13 | 46 | 16 | −39 |
| Free cash flow after stock pay | −32 | −31 | −43 | −51 | −19 | 41 | 12 | −43 |
| Shares issued | 52 | 4 | 4 | 5 | 0 | 5 | 14 | 114 |
Compare with peers
- Mannkind Corp cash flow
- Sinovac Biotech LTD cash flow
- Novavax Inc cash flow
- Pharming Group N.V. cash flow
- Ardelyx, Inc. cash flow
Head to head: MGTX vs MNKDMGTX vs SVAMGTX vs NVAXMGTX vs PHAR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies